Responses

Download PDFPDF

Extended report
Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Malignancies and abatacept. Commentary on the article by Simon et al.

    Dear editor,

    In the Dec 3, 2008 online issue of The Annals, Simon et al did a comparison of the rate of cancers occurring in the rheumatoid arthritis (RA) abatacept clinical development program with malignancies occurring in five observational RA cohorts (1). The main result of this study is that the rate of cancers in patients included in the clinical trials of abatacept is the same than in RA cohorts.

    This typ...

    Show More
    Conflict of Interest:
    None declared.